CMS1 (MSI immune, ~14%) is characterized by high MSI due to MMR deficiency and frequent BRAF mutations, resulting in abundant neoantigen expression, significant intratumoral immune cell infiltration, and the pronounced activation of immune evasion pathways. This evidence concerns the gene BRAF and mismatch repair cancer syndrome 1.